Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Mar;79(7-8):1185–1189. doi: 10.1038/sj.bjc.6690190

Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis

A Abudu 1, D C Mangham 1, G M Reynolds 1, P B Pynsent 1, R M Tillman 1, S R Carter 1, R J Grimer 1
PMCID: PMC2362218  PMID: 10098757

Abstract

Biopsy tissues of 52 patients with Ewing's sarcoma of bone treated between 1983 and 1993 were examined immunohistochemically to determine the significance of p53 protein in diagnosis and prognosis of Ewing's sarcoma. Mean age at diagnosis was 17 years (range 6–36) and minimum follow-up was 30 months. The tumours were located in the extremities and central bones in 35 and 17 patients respectively. Metastases were present in seven patients at diagnosis. Treatment consisted of chemotherapy, surgery and/or radiotherapy in all the patients. Overexpression of p53 protein was demonstrated in seven patients (14%). There was no relationship between expression of p53 and site of tumours. Patients who overexpressed p53 protein appeared to have more advanced diseases at diagnosis and poorer response to chemotherapy than those without p53 overexpression. The 5-year relapse-free survival and overall survival in patients without metastases at the time of diagnosis were 66% and 71%, respectively, in p53 protein-negative patients compared with 20% relapse-free and overall survival in those with p53 protein overexpression (P = 0.01). The poorer prognosis in p53 protein-positive patients was independent of site, local treatment or necrosis of the tumours (P < 0.05). Over-expression of p53 protein is an independent poor prognostic factor in Ewing's sarcoma of bone. © 1999 Cancer Research Campaign

Keywords: p53, Ewing's sarcoma, tumour suppressor

Full Text

The Full Text of this article is available as a PDF (83.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartek J., Iggo R., Gannon J., Lane D. P. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene. 1990 Jun;5(6):893–899. [PubMed] [Google Scholar]
  2. Cangir A., Vietti T. J., Gehan E. A., Burgert E. O., Jr, Thomas P., Tefft M., Nesbit M. E., Kissane J., Pritchard D. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer. 1990 Sep 1;66(5):887–893. doi: 10.1002/1097-0142(19900901)66:5<887::aid-cncr2820660513>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  3. Cattoretti G., Becker M. H., Key G., Duchrow M., Schlüter C., Galle J., Gerdes J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol. 1992 Dec;168(4):357–363. doi: 10.1002/path.1711680404. [DOI] [PubMed] [Google Scholar]
  4. Cordon-Cardo C., Latres E., Drobnjak M., Oliva M. R., Pollack D., Woodruff J. M., Marechal V., Chen J., Brennan M. F., Levine A. J. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994 Feb 1;54(3):794–799. [PubMed] [Google Scholar]
  5. Davidoff A. M., Humphrey P. A., Iglehart J. D., Marks J. R. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5006–5010. doi: 10.1073/pnas.88.11.5006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Glass A. G., Fraumeni J. F., Jr Epidemiology of bone cancer in children. J Natl Cancer Inst. 1970 Jan;44(1):187–199. [PubMed] [Google Scholar]
  7. Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994 Sep 15;54(18):4855–4878. [PubMed] [Google Scholar]
  8. Hsu H. C., Tseng H. J., Lai P. L., Lee P. H., Peng S. Y. Expression of p53 gene in 184 unifocal hepatocellular carcinomas: association with tumor growth and invasiveness. Cancer Res. 1993 Oct 1;53(19):4691–4694. [PubMed] [Google Scholar]
  9. Isola J., Visakorpi T., Holli K., Kallioniemi O. P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst. 1992 Jul 15;84(14):1109–1114. doi: 10.1093/jnci/84.14.1109. [DOI] [PubMed] [Google Scholar]
  10. Kovar H., Auinger A., Jug G., Aryee D., Zoubek A., Salzer-Kuntschik M., Gadner H. Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours. Oncogene. 1993 Oct;8(10):2683–2690. [PubMed] [Google Scholar]
  11. Lane D. P. Cancer. A death in the life of p53. Nature. 1993 Apr 29;362(6423):786–787. doi: 10.1038/362786a0. [DOI] [PubMed] [Google Scholar]
  12. Larsson S. E., Lorentzon R. The geographic variation of the incidence of malignant primary bone tumors in Sweden. J Bone Joint Surg Am. 1974 Apr;56(3):592–600. [PubMed] [Google Scholar]
  13. Levine A. J. The p53 tumor-suppressor gene. N Engl J Med. 1992 May 14;326(20):1350–1352. doi: 10.1056/NEJM199205143262008. [DOI] [PubMed] [Google Scholar]
  14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  15. Mendenhall C. M., Marcus R. B., Jr, Enneking W. F., Springfield D. S., Thar T. L., Million R. R. The prognostic significance of soft tissue extension in Ewing's sarcoma. Cancer. 1983 Mar 1;51(5):913–917. doi: 10.1002/1097-0142(19830301)51:5<913::aid-cncr2820510525>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES